Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) is a clinical-stage biopharmaceutical company focused on developing treatments for eye conditions and other diseases. Their lead product, TP-03, is in Phase III trials for blepharitis caused by Demodex mites. Tarsus is also working on TP-04 for rosacea and TP-05 for Lyme disease and malaria prevention. The company competes with other biopharmaceutical firms in the ophthalmic and dermatological sectors.
The consensus price target for Tarsus has fluctuated over the past year, with a decrease from $67 last quarter to $62 last month. This change may reflect shifts in analysts' expectations or market conditions. Despite this, Wall Street analysts, including Francois Brisebois from Oppenheimer, have set a higher price target of $72, indicating optimism for the stock's future performance.
Tarsus has seen a 9.11% decline in its stock price over the past four weeks, placing it in oversold territory. This suggests that the selling pressure may have eased. Analysts have revised earnings estimates higher, hinting at a potential trend reversal. The consensus price target of $72 reflects a possible 41.1% upside, as highlighted by Zacks.
The company's recent Q3 2024 earnings call featured key figures discussing financial performance and strategic direction. Analysts from firms like Goldman Sachs and Barclays attended, with Francois Brisebois setting a $72 price target. Tarsus is expected to surpass earnings estimates, which could positively impact the stock's value.
Tarsus has achieved significant milestones, including FDA approval for Xdemvy, a treatment for demodex blepharitis. The company reported $40.8 million in revenue for Q2 2024 and is expanding its research efforts. With $323 million in cash reserves and anticipated positive cash flow by Q3 2024, Tarsus is financially strong, supporting the optimistic $72 price target.
